Ishikawa, Takayuki

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Bernard, E., Tuechler, H., Greenberg, P. L., Hasserjian, R. P., Arango Ossa, J. E., Nannya, Y., Devlin, S. M., Creignou, M., Pinel, P., Monnier, L., et al. (2022) · NEJM Evidence

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 867

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 648

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., Yimer, H. A., LeBlanc, R., Takezako, N., McCroskey, R. D., et al. (2019) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 251

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood

Iron Metabolism and DisordersAutoimmune and Inflammatory Disorders Research

Cited by 228